Skip to content

✌🏼 Free Shipping on orders $100!

Cart
FDA

FDA's New Vape Enforcement Guidance: Pending PMTAs Get Breathing Room

FDA's New Vape Enforcement Guidance: Pending PMTAs Get Breathing Room

The FDA has issued updated guidance on how it will handle vapes and nicotine pouches sold without premarket authorization, and the shift gives products with pending applications more room to operate. Released May 8, 2026, the FDA vape enforcement guidance 2026 signals that the agency will steer enforcement toward the highest-risk products rather than every unauthorized item on the market.

What happened

On May 8, the FDA published updated guidance outlining its current enforcement approach for electronic nicotine delivery systems (ENDS) and nicotine pouch products that lack premarket authorization. As Tobacco Reporter detailed, the agency emphasized that the policy is nonbinding and reflects its current priorities rather than a change in the underlying law — unauthorized products remain illegal.

The key move: the FDA said it does not intend to prioritize enforcement against products that have pending, sufficiently complete applications under scientific review. In practice, a manufacturer whose Premarket Tobacco Product Application (PMTA) has been accepted, filed, and is being reviewed sits in a lower enforcement-priority tier. The guidance also says enforcement will focus on products carrying higher public health risks — including those that appeal to youth or lack required safety features — and that the agency will maintain a public-facing list of products under review to improve transparency.

Industry figures framed the clarity as overdue. “File a PMTA for your product that includes everything the FDA has explicitly listed they expect to see, wait 180 days, and then you can launch your product in the market,” Laura Leigh Oyler, Vice President of Regulatory Affairs for Nicokick.com, told Tobacco Reporter, calling the announcement “mind-blowingly clear” for an agency that often operates without much of it.

Why it matters

For years, the line between legal and illegal in the vape market has been blurry. Thousands of products have been sold while their applications sat in review, leaving retailers and manufacturers unsure where enforcement would land. By publicly tiering enforcement — authorized products, filed-PMTA products, and unauthorized products with no application at all — the FDA is giving the market a clearer map of risk.

It’s important to be precise about what this does and doesn’t do. The guidance is nonbinding and does not make pending products legal; it describes where the agency intends to direct its limited enforcement resources. Products with no application, and those flagged for youth appeal or missing safety features, remain squarely in the enforcement crosshairs.

“This is a ground-breaking announcement for American consumers who deserve a wealth of options.” — Laura Leigh Oyler, Nicokick.com, via Tobacco Reporter

What this means for vapers

The practical effect for buyers is a market that leans harder toward products whose manufacturers have filed complete PMTAs and are transparent about their status. The FDA’s promise of a public-facing list of products under review is a tool worth knowing about — it gives consumers and retailers a way to check where a product stands. Alongside state-level actions that tie legal sale to FDA authorization, federal enforcement priorities increasingly reward brands that have done the regulatory paperwork.

For anyone building a go-to rotation of devices, the signal is to favor established brands that are engaged in the PMTA process over no-name products with no application on file. Those unauthorized, unfiled products are the ones most exposed to enforcement — including seizure of imported shipments — and the most likely to disappear from shelves.

The bottom line

The FDA’s May 2026 guidance doesn’t rewrite the law, but it clarifies the rules of engagement: pending, filed PMTAs get lower enforcement priority, while unapplied and high-risk products stay in the line of fire. Paired with state moves that lean on FDA authorization, the federal message is consistent — the market is being nudged toward products with a documented regulatory path. Adult vapers and retailers alike benefit from knowing which side of that line their favorites fall on.

This product contains nicotine. Nicotine is an addictive chemical. For adults 21+ only.